Date: Sunday, November 8, 2015
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: ABT-981 is a novel human Dual-Variable Domain Immunoglobulin (DVD-Ig™) that inhibits interleukin (IL)-1α and IL-1β. The purpose of this study is to evaluate IL-1α and IL-1β protein levels in serum, and IL-1α, IL-1β, and IL-1Ra (IL-1 receptor antagonist) mRNA levels in peripheral blood leukocytes (PBLs) in patients with knee osteoarthritis (OA).
Methods: In a randomized, double-blind, placebo (PBO)-controlled, multiple dose study (NCT01668511), 27 knee OA patients received ABT-981 (0.3, 1, or 3 mg/kg; n=7 each group) or PBO (n=6) subcutaneously every 2 wks (4 doses total). Serum samples were collected on days 1 (predose), 5, 15, 19, 29, 33, 43, 47, 57, and 113. Peripheral blood was collected on days 1, 5, 57, and 113. Imperacer® Immuno-PCR assays (Chimera Biotec) were used to detect free protein concentration of IL-1α/IL-1β in serum. Total RNA isolated from PBLs was converted to cDNA for quantitative PCR detection of IL-1a, IL-1b, and IL-1Ra mRNAs. Changes in biomarkers in ABT-981 groups were compared with baseline (BL) and PBO. Repeated measures analysis was performed using SAS 9.2. Adjusted P values were calculated using Bonferroni method.
Results: Mean BL serum IL-1α level was 7.1 pg/mL. In all ABT-981 groups serum IL-1α levels significantly (P<.001) decreased from day 5 to 57 (2 wks after last dose), a decrease of 75-95% from BL. Decreases were maintained until day 113 in 1 (-69.8%, P<.001) and 3 mg/kg groups (-58.3%, P=.005). IL-1α level in 0.3 mg/kg group recovered to near BL level on day 113. Compared with PBO, serum IL-1α levels in all ABT-981 groups were significantly decreased from day 5 to 113 (P<.001). Mean BL serum IL-1β level was 0.46 pg/mL. In the 1 and 3 mg/kg groups serum IL-1β levels significantly decreased 48.7-87.1% from BL (P≤.01) throughout the study. Compared with PBO, serum IL-1β levels were significantly decreased in the 1 and 3 mg/kg groups (P<.001), and a downward trend was observed in 0.3 mg/kg group (P=.034). PBL IL-1a mRNA was undetectable in all dose groups and at all time points. At day 5, IL-1b mRNA expression significantly decreased in 3 mg/kg group (P<.001) and a downward trend in 1 mg/kg group (P=.092). IL-1Ra mRNA expression levels in PBLs did not show dose dependent changes in the treatment groups.
Conclusion: Simultaneous robust inhibition serum of IL-1α and IL-1β with ABT-981 was observed in this study in a dose-dependent manner. The prolonged inhibition of IL-1α and IL-1β in the 1 and 3 mg/kg groups indicates a long lasting biological effect of ABT-981 even after the drug has been ~97% cleared from the system (day 113). The dose-dependent decrease of IL-1b mRNA expression in PBLs on day 5 coincides with decrease in serum IL-1β protein. However, transient decrease in PBL IL-1b mRNA, despite persistent decreases in serum IL-1a and IL-1b levels, suggest that other cytokines also play a role in regulating IL-1b transcription in these cells. In conclusion, serum levels of IL-1a and IL-1b proteins and PBL IL-1b mRNA are dose-dependently inhibited in knee OA subjects dosed with ABT-981 and represent candidate measurements of target engagement.
To cite this abstract in AMA style:Wang SX, Loebbert R, Sampson E, Saltarelli M, Medema J, Hong F. Dual Variable Domain-Immunoglobulin (Dvd-Igâ„¢) Abt-981 Simultaneously and Dose-Dependently Inhibits Interleukin-1 Î‘lpha and -1 Î’eta in Subjects with Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/dual-variable-domain-immunoglobulin-dvd-iga%c2%a2-abt-981-simultaneously-and-dose-dependently-inhibits-interleukin-1-ilpha-and-1-ieta-in-subjects-with-knee-osteoarthritis/. Accessed January 27, 2022.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/dual-variable-domain-immunoglobulin-dvd-iga%c2%a2-abt-981-simultaneously-and-dose-dependently-inhibits-interleukin-1-ilpha-and-1-ieta-in-subjects-with-knee-osteoarthritis/